Latest news

• Alnylam’s amyloidosis drug heads latest crop of CHMP approvals

  It also backed three targeted cancer drugs: Pierre Fabre’s BRAF inhibitor Braftovi (encorafenib) and MEK inhibitor Mektovi (binimetinib) as a combination for BRAF V600-positive melanoma; and Eli Lilly’s ... CDK4/6 inhibitor Verzenios (abemaciclib)

• Alnylam’s amyloidosis drug heads latest crop of CHMP approvals

  It also backed three targeted cancer drugs: Pierre Fabre’s BRAF inhibitor Braftovi (encorafenib) and MEK inhibitor Mektovi (binimetinib) as a combination for BRAF V600-positive melanoma; and Eli Lilly’s ... CDK4/6 inhibitor Verzenios (abemaciclib)

• FDA backs earlier use of Lilly’s breast cancer drug Verzenio

  Eli Lilly has picked up yet another FDA approval for CDK4/6 inhibitor Verzenio - its third in five months - as it tries to chase down Pfizer’s category-leading Ibrance. ... year and is predicted to become a $6bn product at peak by EvaluatePharma - as

• Novartis bags new breakthrough status for Kisqali in breast cancer

  show that a CDK4/6 inhibitor can have a benefit in this setting. ... Meanwhile Novartis is trying to keep its new drug ahead of Eli Lilly’s CDK4/6 inhibitor Verzenio (abemaciclib), which was approved in the US - its first market - last September.

• Novartis raises pressure in Pfizer’s Ibrance with new Kisqali data

  New phase III data for Novartis’CDK4/6 inhibitor Kisqali has shown that the drug is effective in tackling breast cancer in younger women. ... Novartis is currently a little ahead of Eli Lilly, whose CDK4/6 inhibitor Verzenio (abemaciclib) was approved